Intellia Therapeutics (NTLA) Receives Coverage Optimism Score of 0.12

Press coverage about Intellia Therapeutics (NASDAQ:NTLA) has been trending somewhat positive on Tuesday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Intellia Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.1456856651287 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

NTLA has been the subject of a number of recent analyst reports. TheStreet upgraded shares of Intellia Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 19th. Wedbush reiterated an “outperform” rating and set a $36.00 target price on shares of Intellia Therapeutics in a research note on Thursday, March 15th. BidaskClub upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. JMP Securities started coverage on shares of Intellia Therapeutics in a research note on Thursday, March 8th. They set an “outperform” rating for the company. Finally, Leerink Swann reiterated an “outperform” rating on shares of Intellia Therapeutics in a research note on Wednesday, March 14th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $34.83.

Shares of NTLA opened at $21.75 on Tuesday. Intellia Therapeutics has a 1-year low of $11.15 and a 1-year high of $35.99.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Wednesday, March 14th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16). The company had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $8.84 million. Intellia Therapeutics had a negative net margin of 258.62% and a negative return on equity of 31.27%. Intellia Therapeutics’s quarterly revenue was up 19.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.31) earnings per share. equities research analysts forecast that Intellia Therapeutics will post -2.27 earnings per share for the current fiscal year.

In other news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jean Francois Formela sold 39,245 shares of the business’s stock in a transaction on Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total transaction of $936,778.15. The disclosure for this sale can be found here. Insiders own 12.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2018/04/17/intellia-therapeutics-ntla-receives-coverage-optimism-score-of-0-12.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Insider Buying and Selling by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply